Ross is the second generation of the Morton Family office who are leaders and investors in the British Life Sciences community. They have exited $2B in biotech, medtech and pharma companies with special focus on oncology and rare disease products.

A successful Founder in his own right Ross has built and sold two single-asset biotech companies in immunology and rare disease. Most recently Ross has spearheaded the spin-out of his FOs Life Sciences investing to a Venture Fund called Nodenza.

Nodenza focuses on giving fellow families access to the Life Sciences vertical delivered by the Morton’s deep industry expertise.